Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120551 | 1.00 | CA2 (0.57) | CA2CPB2CA1ZDHHC7MAPK1 | |
| SCHEMBL28793337 | 1.00 | CA2 (0.57) | CA2CPB2CA1ZDHHC7MAPK1 | |
| SCHEMBL18143477 | 1.00 | CA2 (0.57) | CA2CPB2CA1ZDHHC7MAPK1 | |
| SCHEMBL625957 | 1.00 | CA2 (0.57) | CA2CPB2CA1ZDHHC7MAPK1 | |
| SCHEMBL9000340 | 1.00 | CA2 (0.57) | CA2CPB2CA1ZDHHC7MAPK1 | |
| SCHEMBL25341592 | 0.98 | CPB2 (0.58) | CA2CPB2CA1ZDHHC7GRIK1 | |
| SCHEMBL5516547 | 0.98 | CPB2 (0.58) | CA2CPB2CA1ZDHHC7GRIK1 | |
| SCHEMBL18531126 | 0.98 | CPB2 (0.58) | CA2CPB2CA1ZDHHC7GRIK1 | |
| SCHEMBL19148651 | 0.98 | CPB2 (0.58) | CA2CPB2CA1ZDHHC7GRIK1 | |
| SCHEMBL5580131 | 0.98 | CPB2 (0.58) | CA2CPB2CA1ZDHHC7GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946101-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | VYNE THERAPEUTICS INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-20210015927-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | SWK FUNDING LLC | 2021-01-21 | — | — | US | claimed |
| US-20190134204-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | SWK FUNDING LLC | 2019-05-09 | — | — | US | claimed |
| US-10137200-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | FOAMIX PHARMACEUTICALS LTD. (IL) | 2018-11-27 | — | — | US | claimed |
| US-20180193469-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | FOAMIX PHARMACEUTICALS LTD. (IL) | 2018-07-12 | — | — | US | claimed |
| US-8945516-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-02-03 | — | — | US | claimed |
| CN-114469991-A | Selenium disulfide composition for treating meibomian gland dysfunction | 阿祖拉眼科有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20100111884-A1 | UV ABSORBER FORMULATIONS | CIBA CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111884-A1 | UV ABSORBER FORMULATIONS | C1R, C1S, C9 | CA2 2370/4885CPB2 1249/4885CA1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.